Amgen Patent Ruling's Impact Extends Beyond Life Sciences

Summary

Law360 (September 12, 2023, 5:20 PM EDT) -- In Amgen Inc. v. Sanofi, the U.S. Supreme Court in May further clarified the patent enablement requirement.[1] At issue in the case were Amgen's patents that claimed a wide class of antibodies that perform two cholesterol-lowering functions. The patent specifications, however, described only 26 antibodies that would belong to that class.[2]